title: Linaclotide, a new direction in the treatment of irritable bowel syndrome and chronic constipation.
abstract: Microbia Inc is developing the oral guanylate cyclase C agonist linaclotide, a 14mer peptide for the potential treatment of constipation-predominant irritable bowel syndrome and chronic idiopathic constipation. Phase II clinical trials are underway for both indications.
authors: Mayo Clinic School of Medicine, Division of Gastroenterology & Hepatology, 13400 East Shea Blvd, Scottsdale, AZ 85259, USA. Harris.Lucinda@mayo.edu
authors: Lucinda A
authors: LA
authors: Harris
authors: Michael D
authors: MD
authors: Crowell
mesh_terms: D000818:Animals; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D003248:Constipation / Q000188:drug therapy*; D006801:Humans; D043183:Irritable Bowel Syndrome / Q000188:drug therapy*; D015394:Molecular Structure; D010455:Peptides / Q000737:chemistry / Q000378:metabolism / Q000627:therapeutic use*
chemical_list: D010455:Peptides; C523483:linaclotide